TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra

What It Covers

Stig Brodersen, Tobias Carlisle, and Hari Ramachandra pitch three stocks trading at significant discounts: Novo Nordisk at 12x forward earnings after a 40% decline, S&P Global at 23x PE after five years of sideways movement, and Deckers Outdoor at 11x earnings with $1.6B net cash on its balance sheet.

Key Questions Answered

• •Novo Nordisk downside protection: At 12x forward earnings versus Eli Lilly's 24x, Novo's base case offers 8-9% annual returns including a 4.5% dividend yield with a 50% payout ratio. The market prices Novo as permanently second in GLP-1 drugs, but its oral semaglutide pill is already tracking toward $2B in annual revenue, and amycretin enters Phase 3 trials with results expected by 2028.
• •S&P Global ratings moat structure: The ratings duopoly between S&P (45% share) and Moody's (40%) functions as a complement, not a competition — issuers need both ratings simultaneously. Regulatory mandates reinforce this, and companies that skip major agency ratings face adverse selection, paying higher borrowing costs. Surveillance fees on existing ratings create recurring revenue beyond initial issuance, compounding the moat over time.
• •S&P Global valuation entry point: Stig initiated a 1% position at $399, his first new holding in over a year, estimating intrinsic value at $450-$500. Revenue guidance of 6-8% growth combined with a ~2% buyback yield and ~1% dividend suggests low double-digit annual returns. The PE compressed from 40x in 2021 to 23x today entirely on multiple contraction, not earnings deterioration.
• •Market Intelligence AI risk is overstated: S&P Global's Market Intelligence segment, roughly equal to ratings in revenue but generating only 17.9% of operating profit, faces disruption from AI-native competitors like AlphaSense ($600M ARR) and Rogo ($50M ARR). However, this segment represents only 6-8% of S&P's total market cap if spun off, making its disruption immaterial to the overall investment thesis even in a worst-case scenario.
• •Deckers capital allocation as downside floor: Deckers carries $1.6B net cash, zero debt, and directs 80% of free cash flow to buybacks, reducing share count 7% year-over-year. The buyback authorization of $4.7B exceeds 40% of market capitalization. In a bear scenario assuming 2% growth and an 8x terminal multiple, fair value lands at $72 versus the $77 current price, limiting downside materially.
• •Scenario analysis framework for consumer brands: Tobias structures Deckers across three scenarios: bear case (2% growth, 8x multiple) yields $72 fair value; base case (3% growth, 11x multiple) yields $113; bull case (4% growth, 14x multiple) yields $160. He assigns 20% probability to each tail and 60% to the base case, producing a probability-weighted fair value of roughly $110-$115 against a $77 current price.